Bullfrog AI (NASDAQ:BFRG) versus Ginkgo Bioworks (NYSE:DNA) Critical Comparison

Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Bullfrog AI and Ginkgo Bioworks’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bullfrog AI N/A -150.36% -127.98%
Ginkgo Bioworks -259.96% -60.27% -26.88%

Volatility & Risk

Bullfrog AI has a beta of -2.73, indicating that its share price is 373% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bullfrog AI and Ginkgo Bioworks”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bullfrog AI $298,798.00 31.40 -$6.50 million ($0.46) -1.10
Ginkgo Bioworks $170.15 million 5.06 -$312.76 million ($5.01) -2.55

Bullfrog AI has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bullfrog AI and Ginkgo Bioworks, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bullfrog AI 1 1 0 0 1.50
Ginkgo Bioworks 2 2 0 0 1.50

Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential downside of 45.28%. Given Ginkgo Bioworks’ higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Bullfrog AI.

Summary

Ginkgo Bioworks beats Bullfrog AI on 6 of the 11 factors compared between the two stocks.

About Bullfrog AI

(Get Free Report)

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Ginkgo Bioworks

(Get Free Report)

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.